Loading the session
Loading the session
Loading instrument
$23.30
+2.64%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:30 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −1.6% (SPY −1.6%, XLV +13.5%). 3 months: −16.9% (SPY −0.4%, XLV +15.5%). 1 year: +107.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ANRO, SPY and XLV · as of 4 Nov 2026
5.2M shares were sold short at the 15 Oct 2026 settlement, 13.3% of the 39.2M shares outstanding; covering them would take 7.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $23.30 was 15.3% below its 50-day average ($27.50) and 4.3% below its 200-day average ($24.34). It has closed below the 200-day for 11 sessions, since 21 Oct 2026. The 50-day average crossed above the 200-day on 11 Sep 2025, 289 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $23.30 on 4 Nov 2026: 37.8% below the 52-week high of $37.48 (25 Aug 2026) and 119.4% above the low of $10.62 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
October 20, 2025
+80.92%October 3, 2025
+56.24%October 23, 2024
−69.99%